Estrogen regulates Hippo signaling via GPER in breast cancer

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 2123-2135

  Zhou, Xin ^a,b,c   Wang, Shuyang ^a   Wang, Zhen ^a,b,c   Feng, Xu ^a,b,c   Liu, Peng ^a,b,c   Lv, Xian Bo ^a,b,c   Li, Fulong ^a,b,c   Yu, Fa Xing ^b   Sun, Yiping ^a,b   Yuan, Haixin ^a,b   Zhu, Hongguang ^a   Xiong, Yue ^b,c,d   Lei, Qun Ying ^a,b   Guan, Kun Liang ^a,b,e  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN; TAZ PROTEIN; UNCLASSIFIED DRUG; YAP PROTEIN; GPER PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HIPPO PROTEIN, HUMAN; LATS1 PROTEIN, HUMAN; PHOSPHOLIPASE C BETA; PHOSPHOPROTEIN; PLCB1 PROTEIN, HUMAN; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE; RHO KINASE; ROCK1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STK3 PROTEIN, HUMAN; STK4 PROTEIN, HUMAN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER SIZE; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MYOEPITHELIUM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL DIVISION; CELL MOTION; CELL TRANSFORMATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PAGET NIPPLE DISEASE; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; RNA INTERFERENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHOLIPASE C BETA; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RHO-ASSOCIATED KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84928984549     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79573     Document Type: Article

References (50)

1. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001;29(14):2905-2919.
2. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296(5573):1642-1644.
3. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997;45(3):607-617.
4. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307(5715):1625-1630.
5. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7(2):79-94.
6. O'Hayre M, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer. 2013;13(6):412-424.
7. Filardo EJ, Quinn JA, Bland KI, Frackelton AR, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;14(10):1649-1660.
8. Maggiolini M, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279(26):27008-27016.
9. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009;28(5):523-532.
10. Albanito L, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007;67(4):1859-1866.
11. Vivacqua A, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006;20(3):631-646.
12. Ignatov A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat. 2011;128(2):457-466.
13. Filardo EJ, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res. 2006;12(21):6359-6366.
14. Kuo WH, et al. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan J Obstet Gynecol. 2007;46(2):135-145.
15. Poola I, Abraham J, Liu A, Marshalleck JJ, Dewitty RL. The cell surface estrogen receptor, G Protein-coupled Receptor 30 (GPR30), is markedly down regulated during breast tumorigenesis. Breast Cancer (Auckl). 2008;1:65-78.
16. Pan D. Hippo signaling in organ size control. Genes Dev. 2007;21(8):886-897.
17. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24(9):862-874.
18. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246-257.
19. Zhao B, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747-2761.
20. Dong J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120-1133.
21. Lei QY, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008;28(7):2426-2436.
22. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008;283(9):5496-5509.
23. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010;24(1):72-85.
24. Liu CY, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem. 2010;285(48):37159-37169.
25. Huang W, et al. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrC-P-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem. 2012;287(31):26245-26253.
26. Zhao B, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962-1971.
27. Zhang H, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009;284(20):13355-13362.
28. Murakami H, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71(3):873-883.
29. Chan SW, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008;68(8):2592-2598.
30. Cordenonsi M, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147(4):759-772.
31. Yu FX, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780-791.
32. Miller E, et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem Biol. 2012;19(8):955-962.
33. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618-629.
34. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609-1618.
35. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146(2):624-632.
36. Bologa CG, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2(4):207-212.
37. Dennis MK, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009;5(6):421-427.
38. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10(1):47-60.
39. Kurt AH, Buyukafsar K. Vasoconstriction induced by G1, a G-protein-coupled oestrogen receptor1 (GPER-1) agonist, in the isolated perfused rat kidney. Eur J Pharmacol. 2013;702(1):71-78.
40. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012;26(1):54-68.
41. Dupont S, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474(7350):179-183.
42. Sawada K, et al. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol Oncol. 2002;87(3):252-259.
43. Ruiz-Loredo AY, Lopez E, Lopez-Colome AM. Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation. J Cell Physiol. 2011;226(2):414-423.
44. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24(12):2076-2086.
45. Glantschnig H, Rodan GA, Reszka AA. Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J Biol Chem. 2002;277(45):42987-42996.
46. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002;16(6):592-594.
47. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116(3):561-570.
48. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy hormonal therapy for early breast cancer on recurrence 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
49. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat. 2010;123(1):87-96.
50. Lei Q, et al. NKX3.1 stabilizes p53, inhibits AKT activation, blocks prostate cancer initiation caused by PTEN loss. Cancer Cell. 2006;9(5):367-378.